Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome

Journal of Clinical Microbiology

Volumn 41, Issue 8, 2003, Pages 3615-3622

  Gaudy, Catherine ^a   Moreau, Alain ^a   Veillon, Pascal ^b   Temoin, Stephanie ^a   Lunel, Francoise ^b   Goudeau, Alain ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; BASE SEQUENCE; COMPLEMENTARITY DETERMINING REGIONS; DNA PRIMERS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAQ POLYMERASE; TREATMENT OUTCOME; VARIATION (GENETICS);

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0041522557     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.8.3615-3622.2003     Document Type: Article

References (45)

1. Blanchard, E., D. Brand, S. Trassard, A. Goudeau, and P. Roingeard. 2002. Hepatitis C virus-like particle morphogenesis. J. Virol. 76:4073-4079.
2. Di Marzo Veronese, F., M. S. Reitz, G. Gupta, M. Robert-Gouroff, C. Boyer-Thompson, R. C. Gallo, and P. Lusso. 1993. Loss of a neutralizing epitope by a spontaneous point-mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J. Biol. Chem. 268:25894-25901.
3. Duarte, E. A., I. S. Novella, S. C. Weaver, E. Domingo, S. Wain-Hobson, and D. K. Clarke. 1994. RNA virus quasispecies: significance for viral disease and epidemiology. Infect. Agents Dis. 3:201-214.
4. Farci, P., A. Shimoda, A. Coiana, G. Diaz, G. Peddis, J. C. Meldoper, A. Strazzera, D. Y. Chien, S. J. Munoz, A. Balestrieri, R. H. Purcell, and H. J. Alter. 2000. The outcome of acute hepatitis C predicted by evolution of viral quasispecies. Science 288:339-344.
5. Farci, P., A. Shimoda, D. Wong, T. Cabezon, D. De Giovannis, A. Strazzera, Y. Shimizu, M. Shapiro, H. J. Ater, and R. H. Purcell. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA 93:15394-15399.
6. Forns, X., R. Thimme, S. Govindarajan, S. U. Emerson, R. H. Purcell, F. V. Chisari, and J. Bukh. 2000. Hepatitis C virus lacking the second envelope protein is infectious and causes resolving or persistent infection in chimpanzees. Proc. Natl. Acad. Sci. USA 97:13318-13323.
7. Gonzalvez-Peralta, R. P., K. Qian, J. Y. She, G. L. Davis, T. Ohno, M. Mizokami, and J. Y. Lau. 1996. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J. Med. Virol. 49:242-247.
8. Grantham, R. 1974. Amino acid difference formula to help explain protein evolution. Science 185:862-864.
9. Higashi, Y., S. Kakuma, K. Yoshioka, T. Wakita, M. Mizokami, K. Ohba, Y. Ito, T. Ishikawa, M. Takayanagi, and Y. Nagai. 1993. Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 197:659-668.
10. Hino, K., M. Korenaga, E. Orito, Y. Katoh, Y. Yamaguchi, F. Ren, A. Kitase, Y. Satoh, D. Fujiwara, and K. Okita. 2002. Constrained genomic and conformational variability of the hypervariable region 1 of the hepatitis C virus in chronically infected patients. J. Viral Hepat. 9:194-201.
11. Hino, K., D. Yamaguchi, D. Fujiwara, Y. Katoh, M. Korenaga, M. Okazaki, M. Okuda, and K. Okita. 2000. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J. Viral Hepat. 7:36-42.
12. Koizumi, K., N. Enomoto, M. Kurosaki, T. Murakami, N. Izumi, F. Marumo, and C. Sato. 1995. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22:30-35.
13. Kumar, U., J. Brown, J. Montjardino, and H. C. Thomas. 1993. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J. Infect. Dis. 167:726-730.
14. Kurosaki, M., N. Enomoto, F. Marumo, and C. Sato. 1993. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18:1293-1299.
15. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.
16. Lechner, S., K. Rispeter, H. Meisel, W. Kraas, G. Jung, M. Roggendorf, and A. Zibert. 1998. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology 243:313-321.
17. Lee, J. H., T. Stripf, W. K. Roth, and S. Zeuzem. 1997. Non-isotopic detection of hepatitis C virus quasispecies by single-strand polymorphism. J. Med. Virol. 53:245-251.
18. Le Guen, B., G. Squadrito, B. Nalpas, P. Berthelot, S. Pol, and C. Brechot. 1997. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 25:1250-1254.
19. Lopez-Labrador, F. X., S. Ampurdanes, M. Gimenez-Barcons, M. Guilera, J. Costa, M. T. Jimenez de Anta, J. M. Sanchez-Tapias, J. Rodes, and J. C. Saiz. 1999. Relationship of genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection. Hepatology 29:897-903.
20. Martinot-Peignoux, M., P. Marcellin, M. Pouteau, C. Castelnau, N. Boyer, M. Poliquin, C. Degott, I. Descombes, V. Le Breton, M. Milotova, J. P. Benhamou, and S. Erlinger. 1995. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 22:1050-1056.
21. Naito, M., N. Hayashi, T. Moribe, H. Hagiwara, E. Mita, Y. Kanazawa, A. Kasahara, H. Fusamoto, and T. Kamada. 1995. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease. Hepatology 22:407-412.
22. Nei, M., and T. Gojobori. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3:418-426.
23. Odeberg, J., Z. Yun, A. Sönnerborg, M. Uhlen, and J. Lundeberg. 1995. Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. J. Clin. Microbiol. 33:1870-1874.
24. Ogata, N., H. J. Alter, R. H. Miller, and R. H. Purcell. 1991. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. USA 88:3392-3396.
25. Okada, S. I., Y. Akahane, H. Suzuki., H. Okamoto, and S. Mishiro. 1992. The degree of variability in the amino terminal region of the E2/NS1 protein of the hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624.
26. Parker, J. M., D. Guo, and R. S. Hodges. 1986. New hydrophobicity scale derived from high-performance liquid chromatography peptide retention data: correlation of the predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25:5425-5432.
27. Pawlotsky, J. M., G. Germanidis, P. O. Frainais, M. Bouvier, A. Soulier, M. Pellerin, and D. Dhumeaux. 1999. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J. Virol. 73:6490-6499.
28. Penin, F., C. Combet, G. Germanidis, P. O. Frainais, G. Deléage, and J. M. Pawlotsky. 2001. Conservation of the conformation and positive charges of hepatitis charges of the hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 75:5703-5710.
29. Polyak, S. J., S. McArdle, S. L. Liu, D. G. Sullivan, M. Chung, W. T. Hofgärtner, R. L. Carithers, Jr., B. J. McMahon, J. I. Mullins, L. Corey, and D. R. Gretch. 1998. Evolution of the hepatitis C virus quasispecies in the hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72:4288-4296.
30. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
31. Punterio, G., A. Meola, A. Lahm, S. Zuchelli, B. Bruni Ercole, R. Tafi, M. Pezzarena, M. U. Mondelli, R. Cortese, A. Tramontano, G. Galfre, and A. Nicosia. 1998. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 17:3521-3533.
32. Ray, C., Y. M. Wang, O. Laeyendeker, J. R. Ticehurst, S. A. Villano, and D. L. Thomas. 1999. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J. Virol. 73:2938-2946.
33. Sakuma, I., N. Enomoto, M. Kurosaki, F. Marumo, and C. Sato. 1996. Selection of hepatitis C virus quasispecies during interferon treatment. Arch. Virol. 141:1921-1932.
34. Sandres, K., M. Dubois, C. Pasquier, J. L. Payen, L. Alric, M. Duffault, J. P. Vinel, J. P. Pascal, J. Puel, and J. Izopet. 2000. Genetic heterogeneity of the hypervariable region 1 of the hepatitis C virus genome and sensitivity of HCV to alpha interferon therapy. J. Virol. 74:661-668.
35. Scarselli, E., H. Ansuini, R. Cerino, R. M. Roccasecca, S. Acali, G. Filocamo, C. Traboni, A. Nicosia, R. Cortese, and A. Vitelli. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
36. Smith, D. B., J. McAllister, C. Casino, and P. Simmonds. 1997. Virus quasispecies: making a mountain out of a molehill? J. Gen. Virol. 78:1511-1519.
37. Sobolev, B. N., V. V. Poroikov, L. V. Olenina, E. F. Kolesanova, and A. I. Archakov. 2000. Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions. J. Viral Hepat. 7:368-374.
38. Toyoda, H., T. Kumada, S. Nakano, I. Takeda, K. Sugiyama, T. Osada, S. Kiriyama, Y. Sone, M. Kinoshita, and T. Hamada. 1997. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J. Hepatol. 26:6-13.
39. Weiner, A. J., H. M. Geysen, C. Christopherson, J. E. Hall, T. J. Mason, G. Saracco, F. Bonino, K. Crawford, C. D. Marion, K. A. Crawford, M. Brunetto, P. J. Barr, T. Miyamura, J. McHutchinson, and M. Houghton. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA 89:3468-3472.
40. Yagnik, A. T., A. Lahm, A. Meola, R. M. Roccaseca, B. B. Ercole, and A. Nicosia. 2000. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40:355-366.
41. Yamaguchi, K., E. Tanaka, K. Higashi, K. Kiyosawa, A. Matsumoto, S. Furuta, A. Hasegawa, S. Tanaka, and M. Kohara. 1994. Adaptation of hepatitis C virus for persistent infection in patients with acute hepatitis. Gastroenterology 106:1344-1348.
42. Yeh, B. I., K. H. Han, S. H. Oh, H. S. Kim, S. H. Hong, S. H. Oh, and Y. S. Kim. 1996. Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy. J. Med. Virol. 49:95-102.
43. Yun, Z. B., J. Odeberg, J. Lundeberg, O. Weiland, M. Uhlen, and A. Sönneberg. 1996. Restriction of hepatitis C virus heterogeneity during prolonged interferon-α therapy in relation to changes in viral load. J. Infect. Dis. 173:992-996.
44. Zeuzem, S., V. Feinman, J. Rasenack, J. Heathcote, M. Lai, E. Gane, J. O'Grady, J. Reichen, M. Diago, A. Lin, J. Hoffman, and M. J. Brunda. 2000. Peginterferon alpha-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:1666-1672.
45. Zhou, Y. H., Y. K. Shimizu, and M. Esumi. 2000. Monoclonal antibodies to the hypervariable region 1 of the hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro. Virology 269:276-283.